Medical Procedure News

RSS

New minimally-invasive approach to traditional facelift procedure

Adam D. Schaffner, M.D., F.A.C.S., Director of Plastic Surgery at JUVA Skin and Laser Center in Manhattan, is challenging the "one size fits all" approach to the traditional facelift with a new, customizable, minimally-invasive and affordable procedure named JuvaLift.

27 Oct 2010

Blocking receptor contributing to memory deficits may prevent memory loss after anesthesia

Memory loss after anesthesia is a common adverse event upon awakening from surgery. Unfortunately the cause of such memory loss is unknown and there are no known treatments or prevention strategies. A study published in the November 2010 issue of Anesthesiology indicates that this memory loss could be prevented by blocking a receptor thought to contribute to memory deficits. Such a treatment may be able to solve the feeling of mental confusion that surgical patients so often feel shortly after coming out of anesthesia.

27 Oct 2010

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

A new British review of existing research suggests that while a newer type of radiation for the treatment of prostate cancer does not help patients live longer compared to an older type at least when similar doses are given it does appear to reduce gastrointestinal side effects.

27 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Researchers recommend vaginal delivery for breech babies

Most babies are delivered head-first, but in about 4% of all deliveries babies are "born breech" ― with their buttocks or feet first. Doctors usually exercise caution and use caesarean sections (C-sections) as the delivery method of choice for such births, believing it safer for the baby. After a large-scale international study in 2000, C-sections became the near-universal choice for such births.

27 Oct 2010

Opiate substitution treatment reduces mortality risk by 85%

Giving people opiate substitution treatment to help with their drug addiction can lead to a 85% plus chance of reducing mortality, according to a new study published on bmj.com today.

27 Oct 2010

Dobkin technique delays brain damage in heart attack victims

After a heart attack and the victim stops breathing, a process of irreversible brain damage starts to occur within 3 to 4 minutes. Or does it?

27 Oct 2010

IMRT reduces gastrointestinal complications in prostate cancer patients

Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2010

Neurologix holds license for gene therapy to treat severe depression

Neurologix, Inc. today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.

26 Oct 2010

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Stereotactic radiation effective for trigeminal neuralgia

Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that a retrospective study demonstrated that reconstructing the pericardium using ECM Technology in patients undergoing primary isolated coronary artery bypass grafting (CABG) contributed to a statistically significant and clinically meaningful reduction in the rate of new onset postoperative atrial fibrillation.

26 Oct 2010

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Chemoradiotherapy can reduce bladder cancer recurrence

A major bladder cancer trial, funded by Cancer Research UK, has shown that adding two commonly used chemotherapy drugs to traditional radiotherapy can reduce the chance of a patient's tumour coming back by a third.

26 Oct 2010

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

Combination of chemotherapy and radiation improves control of cancer within bladder

Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Tengion, Inc., a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit™ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal.

25 Oct 2010

ThermalTherapeutic Systems, Applied Medical enter strategic alliance

ThermalTherapeutic Systems, Inc., the developer of a highly portable platform technology designed to standardize hyperthermic perfusion treatments, today announced a strategic alliance with Applied Medical Products and Solutions of Boston, MA.

25 Oct 2010